Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience
Inclisiran should be considered as a viable therapeutic alternative for the management of pure hypercholesterolemia in patients with CKD who are intolerant to statin treatment because it achieves the optimal LDL cholesterol targets required by actual guidelines without side effects.
Authors
- N. Miani
- Paola Peverini
- Andrea Dello Strologo (ORCID: https://orcid.org/0000-0001-9128-6638)
- Paolo Lido (ORCID: https://orcid.org/0000-0003-0293-5849)
- Antonio Bellasi (ORCID: https://orcid.org/0000-0001-7830-1645)
- Aldo Franculli (ORCID: https://orcid.org/0000-0003-0730-9054)
- Pasquale Saporito
- Di Lullo L
- Claudio Ronco
Publication Details
- Journal
- Cardiorenal Medicine
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1159/000549898
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00